
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune SA is positioned favorably within the biopharmaceutical market due to its innovative portfolio targeting neurodegenerative diseases, particularly through its development of therapeutic and diagnostic products aimed at misfolded proteins. The anticipated results from the upcoming EVOKE trial and promising data from the ACI-7104.056 program, which has shown a significant increase in antibodies against pathogenic variants, highlight the potential for strong clinical efficacy and safety in treatments. Additionally, the company's focus on timely patient identification and easy-to-administer maintenance therapies aligns with market needs, reinforcing a positive outlook for the company's future growth and potential success in the Alzheimer's disease treatment landscape.
Bears say
AC Immune SA reported a net operating loss of CHF 16.2 million for the quarter, indicating ongoing financial challenges as the company continues to advance its clinical trials. For the 2025 fiscal year, the net loss expanded to CHF 70.4 million, accompanied by a basic and diluted earnings per share (EPS) of (0.70), further reflecting the company's struggles to achieve profitability. Additionally, AC Immune faces multiple industry-specific risks, such as unpredictable clinical outcomes, regulatory hurdles, and the complexities of entering an evolving and price-sensitive market for neurodegenerative disease treatments.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares